Contineum Therapeutics CTNM
Contineum Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$9.15+1.78%close on Oct. 28, 2026 · volume 570K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 8, 2026 | Carmine N. Stengone CEO and President, director | Sold 10b5-1 plan | 2,500 | $16.46 | $41,142 |
| Aug. 3, 2026 | Carmine N. Stengone CEO and President, director | Sold 10b5-1 plan | 2,500 | $16.01 | $40,029 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 10 →Other events · Financial statements and exhibits